Adlai Nortye Completes $100 Million Funding for Immunotherapies
July 13, 2021 at 05:56 AM EDT
Adlai Nortye Biopharma, a Hangzhou oncology immunotherapy company, completed a $100 million Series D round led by CMG-SDIC Capital and existing investor Tigermed. One year ago, Adlai Nortye raised close to $100 million in a Series C funding. Founded in 2016, Adlai Nortye has three candidates in clinical trials and at least ten more undergoing pre-clinical tests. It built the portfolio through collaborations and internal discoveries. It has clinical operation centers in both China and the US . Legend Star and WuXi Biologics' industry fund also participated in the latest funding. More details.... Share this with colleagues: // //
